Repligen Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RGN.F | SRT.F | ALIF-B.ST | 688289.SS | BLFS | DIM.PA | |
|---|---|---|---|---|---|---|
| Market cap | 10.06B | 15.64B | 22.81B | 9.15B | — | 22.26B |
| P/E (TTM) | — | 71.7 | 35.5 | 83.8 | — | 68.7 |
| Forward P/E | 52.1 | 34.5 | 58.9 | 20.2 | — | 37.8 |
| Price/book | 4.8 | 5.8 | 3.8 | 1.3 | — | 5.1 |
| Dividend yield | — | 0.32% | 0.81% | 3.36% | — | 0.31% |
| 1-year change | +27.62% | +28.38% | −0.70% | −28.21% | — | +17.44% |
| Today | −1.47% | −0.66% | +1.46% | +0.89% | 0.00% | +2.33% |
The closest companies by business and industry (Medical Instruments & Supplies). Prices may be delayed up to 15 min.
Latest news
All RGN.F news ›Repligen announces $1 Billion private convertible senior notes transaction
Repligen to issue $1B in 2031 convertible notes, refinance debt, and fund a share repurchase. - Repligen (RGEN) on Friday said it has entered into privately negotiated exchange and/or subscription agreements with certain holders of its…
Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Benitec Biopharma (BNTC)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN), Benitec Biopharma (BNTC) and Zymeworks (ZYME) with bullish sentiments. Stifel Nicolaus analyst Daniel Arias maintained a Buy…
Repligen signals at least 25% 2027 top line growth with BioLife, targeting over $1B revenue
Repligen Q3 2026 earnings: record revenue, raised guidance, and BioLife deal boost 2027 outlook. Earnings Call Insights: Repligen (RGEN) Q3 2026 - "We had a record quarter with $209 million of revenue" (President, CEO & Director Olivier…
Repligen (RGEN) Receives a Buy from J.P. Morgan
J.P. Morgan analyst Casey Woodring maintained a Buy rating on Repligen yesterday and set a price target of $200.00. The company’s shares closed yesterday at $175.42. According to TipRanks, Woodring is a 5-star analyst with an average…
Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript
Repligen Corporation (RGEN) Q3 2026 Earnings Call October 27, 2026 8:00 AM EDT Jacob Johnson - Vice President of Investor RelationsOlivier Loeillot - President, CEO & DirectorJason Garland - CFO & Chief Compliance Officer Good morning and…
Repligen (NASDAQ:RGEN) Releases Earnings Results, Beats Expectations By $0.07 EPS
Posted by Sarita Garza on Oct 27th, 2026 Here are the key takeaways from Repligen’s conference call: Read Our Latest Stock Analysis on RGEN Louisiana-Pacific (LPX) Set to Post Quarterly Earnings on Tuesday Wabtec (NYSE:WAB) Stock Rated…
Repligen (NASDAQ:RGEN) Price Target Raised to $180.00
Posted by Kim Johansen on Oct 22nd, 2026 Repligen (NASDAQ:RGEN – Free Report) had its price target increased by Canaccord Genuity Group from $145.00 to $180.00 in a report published on Monday, Marketbeat reports. Canaccord Genuity Group…
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields restricted market appetite for risk. As reported by CNBC, rising Treasury yields put direct,…
Repligen to Report Third Quarter 2026 Financial Results
GlobeNewswire 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026 The Company will issue a press release before…
Repligen Completes BioLife Solutions Acquisition
Both companies will benefit from the respective global connections of each. Why This Matters: Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup. Repligen completed its acquisition of BioLife Solutions,…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net7
- seekingalpha.com5
- globenewswire.com2
- themarketsdaily.com2
- contractpharma.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.